Asthma Market Size, Share and Growth Analysis Report - Forecast Trends and Outlook (2026-2035)

Read more about this report - Request a Free Sample

Asthma Market Overview

Asthma remains a significant public health concern due to its rising prevalence, recurrent exacerbations, and substantial healthcare burden across diverse age groups. Increasing environmental exposures, allergic conditions, and urbanization continue to influence disease patterns and long-term management needs. The market is driven by the growing disease burden, increasing diagnosis rates, improved access to advanced therapies, and ongoing innovations in biologics, inhalation therapies, and personalized treatment approaches. The market is poised to reach USD 48.59 Billion by 2035. Expanding healthcare infrastructure and supportive reimbursement policies further contribute to market growth.

Asthma Market Growth Analysis and Key Influencers

Asthma Market Dynamics

The following section outlines the key factors influencing the growth of the market, including major drivers, restraints, and emerging opportunities.

Asthma Market Growth Drivers

Advancements in Biologic Therapies Are Strengthening the Market Landscape

The increasing adoption of advanced biologic therapies for severe asthma is creating significant momentum in the market by improving disease control and reducing dependence on long-term oral corticosteroids. For instance, in December 2025, a study led by King's College London reported that monthly tezepelumab injections enabled 90% of patients with severe asthma to reduce daily steroid use, while 50% discontinued steroid tablets completely. Additionally, two-thirds of participants experienced no asthma attacks during the year-long trial involving more than 300 patients across 11 countries. These findings highlight the growing clinical value of biologic therapies, supporting continued market expansion through improved treatment outcomes.

Asthma Market Restraints

Limited Access to Affordable Asthma Therapies Continues to Challenge the Market

Limited access to affordable asthma medications remains a significant challenge for the market, particularly among pediatric and low-income populations. For instance, in June 2025, the discontinuation of Flovent HFA by GSK reduced treatment accessibility after its replacement with a higher-priced authorized generic. The decision was linked to increased barriers in insurance coverage and affordability, with U.S. lawmakers citing a rise in asthma-related hospitalizations and deaths. Such access and reimbursement challenges may continue to limit optimal disease management and market growth.

Asthma Market Opportunities

Development of Innovative Inhaled Therapies Is Creating New Growth Potential for the Asthma Market

The growing development of next-generation inhaled therapies for patients with inadequately controlled asthma is expected to create substantial growth potential in the market. For instance, in January 2025, the United States Food and Drug Administration (FDA) accepted the Investigational New Drug application for frevecitinib (KN-002), an inhaled dry powder therapy developed by Kinaset Therapeutics. The company planned a Phase IIb trial after early findings demonstrated targeted lung delivery with reduced airway inflammation and minimal systemic exposure. Such innovations are expected to expand treatment options and support long-term market growth.

Asthma Market Trends

The market is witnessing several trends, including long-acting biologics, advanced inhaled therapies, and personalized treatment approaches.

Rising Adoption of Ultra-Long-Acting Biologics Is Elevating the Market Growth

The increasing adoption of ultra-long-acting biologic therapies is reshaping asthma management by improving treatment convenience and reducing exacerbations. For example, in January 2026, GSK announced Japan's approval of Exdensur (depemokimab), the first ultra-long-acting biologic for severe asthma requiring only two doses annually. Phase III SWIFT trials demonstrated 58% and 48% reductions in annualized asthma exacerbations over 52 weeks. This trend is expected to accelerate the adoption of innovative biologics and strengthen the asthma market.

Asthma Market Share

Inhaled Route of Administration Is Expected to Maintain Market Leadership

The market is segmented by route of administration into inhaled, oral, injectable, and others. Among these, the inhaled segment is expected to dominate due to its ability to deliver medication directly to the lungs, providing rapid symptom control with reduced systemic exposure. For instance, in July 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the world's first lower-carbon beclometasone inhalers using the next-generation HFA-152a propellant while maintaining the same safety, efficacy, and therapeutic benefits. Continued innovation in inhaler technology is expected to reinforce the leadership of the inhaled segment.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Read more about this report - Request a Free Sample

Asthma Market Analysis by Region

The regions included in the report are the United States, the United Kingdom, Germany, France, Italy, Spain, Japan, and India. Among these, the United States is expected to lead the market owing to strong regulatory support, advanced healthcare infrastructure, and continuous introduction of innovative asthma therapies. For instance, in June 2026, the Asthma and Allergy Foundation of America (AAFA) highlighted the United States Food and Drug Administration (FDA) approval of BREZTRI AEROSPHERE and TRIMBOW, both triple-action inhalers that demonstrated improved lung function in large clinical trials involving more than 2,200 adults. Ongoing product approvals and research initiatives are expected to sustain the country's market leadership.

Leading Players in the Asthma Market

Asthma Market Segmentation

Key Questions Answered in the Asthma Market Report

• What was the asthma market value in 2025?
• What is the asthma market forecast outlook for 2026-2035?
• What are the major factors aiding the asthma market demand?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major asthma market trends?
• Which disease severity is expected to dominate the market segment?
• Which drug class is projected to lead the market segment?
• Which route of administration is anticipated to drive the market segment?
• Which age group is likely to dominate the market segment?
• Which distribution channel is likely to dominate the market?
• Who are the key players involved in the asthma market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Research Methodology

This report is developed through a robust mixed-methods research design combining:

• Primary Research: In-depth interviews conducted with 30+ pulmonologists, allergists, respiratory physicians, hospital pharmacists, healthcare providers, and payer representatives across the United States, United Kingdom, Germany, France, Italy, Spain, Japan, and India. Insights were also obtained from key opinion leaders associated with organizations such as the Global Initiative for Asthma (GINA), the American Thoracic Society (ATS), the European Respiratory Society (ERS), and the American Academy of Allergy, Asthma & Immunology (AAAAI).
• Secondary Research: Peer-reviewed publications from The Lancet Respiratory Medicine, The Journal of Allergy and Clinical Immunology, European Respiratory Journal, regulatory filings from the FDA, EMA, PMDA, and CDSCO, ClinicalTrials.gov records, epidemiological data from the WHO, CDC, NIH, GBD Study, and company resources including annual reports, investor presentations, product portfolios, press releases, and official corporate websites.
• Validation: All quantitative estimates are triangulated using top-down and bottom-up market modeling techniques and validated through multiple expert review and feedback cycles.